What is the future for rimonabant in the treatment of obesity
Doggrell, Sheila (2008) What is the future for rimonabant in the treatment of obesity. Review of Endocrinology, December, pp. 14-17.
|pending for publisher's permission (PDF 91kB) |
Administrators only | Request a copy from author
Orlistat and sibutramine only cause modest reductions in body weight. Rimonabant, a cannabinoid receptor 1 antagonist, is a new approach to weight reduction, but is it safe, efficacious, and better than the existing agents?
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500) > Clinical Pharmacology and Therapeutics (111502)|
|Divisions:||Past > QUT Faculties & Divisions > Faculty of Science and Technology|
Past > Schools > School of Life Sciences
|Copyright Owner:||Copyright 2008 Bryn Mawr Communications|
|Deposited On:||13 Jan 2010 08:34|
|Last Modified:||25 May 2011 00:56|
Repository Staff Only: item control page